Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID-19 combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot, which is due later this year.
The delay was largely expected after Moderna said earlier this month that it does not anticipate approval of the shot until 2026 due to the need for more data on the flu vaccine.
Its shares, which have fallen over 30 per cent this year, were marginally higher at $24.20 in premarket trading.
However, the application withdrawal is the latest sign of increased regulatory scrutiny of the vaccine approval process since Robert F. Kennedy Jr. took the top U.S. health job earlier this year.
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday.
Moderna’s decision comes a day after the U.S. Food and Drug Administration said it would require new clinical trials for approval of annual COVID-19 boosters for healthy people under 65.
The combination shot comprises a new COVID vaccine and an influenza vaccine, both under development by Moderna.
Flu vaccine uptake declining nationwide
The company has previously said it does not expect a delay in the FDA’s decision for the next-generation COVID vaccine, which is due by the end of the month.
Shares of the company have been battered by declining COVID revenue as well as investor concerns spurred by the appointment of Kennedy, who is a vaccine skeptic, as secretary of the U.S. Department of Health and Human Services.
Moderna has been banking on revenue from newer mRNA shots to make up for falling sales of its COVID vaccine and less-than-expected uptake of its respiratory syncytial virus vaccine.
The FDA last week approved rival Novavax’s COVID-19 vaccine more than a month after missing the deadline for the shot’s approval, and limited its use to people with conditions that put them at risk due to the illness.
